AOA1 (ataxia oculomotor apraxia-1) results from mutations in aprataxin, a component of DNA strand break repair that removes AMP from 5 -termini. In the present article, we provide an overview of this disease and review recent experiments demonstrating that short-patch repair of oxidative single-strand breaks in AOA1 cell extracts bypasses the point of aprataxin action and stalls at the final step of DNA ligation, resulting in accumulation of adenylated DNA nicks. Strikingly, this defect results from insufficient levels of non-adenylated DNA ligase and short-patch single-strand break repair can be restored in AOA1 extracts, independently of aprataxin, by addition of recombinant DNA ligase.
like PNK encodes a divergent FHA (forkhead-associated) domain [9] . The FHA domains of both aprataxin and PNK facilitate constitutive interactions with protein kinase CK2-phosphorylated XRCC1 (X-ray repair complementing defective repair in Chinese-hamster cells 1) [6, [9] [10] [11] [12] [13] [14] . It is noteworthy that a third member of this divergent FHA domain family has been identified [denoted APLF (aprataxinand PNK-like factor)/PALF (PNK and aprataxin-like FHA protein)/Xip1] and shown to bind CK2-phosphorylated XRCC1 [15] [16] [17] . In fact, all three FHA domain proteins are also sequestered into the DSBR (double-strand break repair) machinery, via FHA domain-mediated interaction with CK2-phosphorylated XRCC4 [6, 15, 18] . It is thus highly likely that aprataxin, PNK and APLF play roles both in SSBR (singlestrand break repair) and DSBR. Aprataxin also associates with PARP-1 [poly(ADP-ribose) polymerase 1] and p53, and additionally with the nucleolar proteins nucleolin, nucleophosmin and UBF-1 (upstream binding factor 1) [12, 19] . The association and partial co-localization of aprataxin with nucleolar proteins is also mediated by the FHA domain, although whether these associations are direct or indirect (e.g. via another protein) remains to be determined. Nevertheless, the association of aprataxin with nucleolar proteins may indicate that SSBR and/or DSBR is particularly important at sites of high transcriptional activity, perhaps to prevent SSBs (single-strand breaks) from blocking gene expression.
Most of the mutations identified in AOA1 to date are located within the HIT domain or just upstream of the C-terminal zinc-finger motif, consistent with a critical requirement for the HIT domain for normal neurological function. Many of these mutations greatly reduce the stability and/or cellular level of aprataxin and may thus be functionally null alleles [12, 20, 21] . Some mutations appear to be associated with later disease onset and/or milder clinical features [8, [22] [23] [24] , which, in some cases, appear to have less impact on aprataxin stability and/or activity [20] . On the basis of sequence comparisons and substrate specificity, aprataxin appears to [20, 25] . Aprataxin has also been reported to process two types of damaged 3 -terminus arising at oxidative DNA breaks, 3 -phosphate and 3 -phosphoglycolate termini, raising the possibility that it is an end-processing factor. However, the activity of aprataxin on such substrates is also very low (k cat ∼0.0003-0.003 s − 1 ). A more likely physiological substrate for aprataxin are 5 -AMP termini, at which AMP is covalently linked to 5 -phosphate through a pyrophosphate bond [26, 27] . DNA strand breaks in which the 5 -terminus is linked to AMP are normal intermediates of DNA ligation, but if they arise before 3 -DNA end processing has occurred, ligation is inhibited. Aprataxin can remove AMP from the 5 -terminus of DNA breaks at such 'abortive' DNA ligation events, effectively 'proofreading' the DNA ligase reaction [26] . In addition to the HIT domain, the C-terminal zinc finger is important for aprataxin activity on 5 -AMP, probably to increase the affinity and/or specificity of aprataxin for 5 -AMP substrates [27] . Although the ability to process 5 -AMP termini is a very elegant activity, it remains to be determined whether or not this type of terminus arises in vivo.
AOA1 and short-patch SSBR
To clarify the nature of the SSBR defect in AOA1, we recently reconstituted AOA1-dependent short-patch SSBR assays in vitro with human and rodent cell extracts [26, 28] . To measure short-patch SSBR, we employed an oligonucleotide duplex harbouring a 1-bp gap with 3 -phosphate termini, a substrate that mimics one of the commonest types of oxidative SSB arising in cells ( Figure 1A ). The SSB also possesses a 5 -AMP and is therefore a substrate for aprataxin. WT (wildtype) extracts efficiently removed AMP from 5 -termini and repaired the SSBs, as indicated by the respective appearance of 32 P-labelled 25-mer and 43-mer ( Figure 1A , lanes 6-8). In contrast, however, AOA1 extracts did not ( Figure 1A , lanes 3-5). It should be noted that SSBR is proficient in AOA1 extracts if the initial SSB lacks 5 -AMP ( [28] and results not shown). A number of truncated oligonucleotide fragments were generated by non-specific nucleolytic activity in these experiments (see asterisks in Figure 1A ), which is common in lymphoblastoid extracts, and which represent degradation of the 3 -terminus of the 32 P-labelled 25-mer. However, this activity did not account for the short-patch repair defect in AOA1 extracts, which was fully complemented by addition of recombinant aprataxin ( Figure 1A , lanes 9-11). The appearance of ligated product in these experiments was dependent upon the presence of dNTPs, confirming that these experiments measured gap repair rather than ligation across the 1-bp gap (results not shown).
The predicted pathway for short-patch repair of SSBs harbouring 5 -AMP in WT cells is depicted in Figure 1(B) . It was considered likely that this pathway arrests in AOA1 extracts at the very beginning, before 3 -DNA end-processing by PNK and/or DNA gap-filling by Polβ (polymerase β), because the presence of AMP at the 5 -terminus might occlude access to the 3 -terminus. Surprisingly, however, the 3 -phosphatase activity of PNK was similar irrespective of whether or not the SSB possessed 5 -AMP, under conditions in which PNK was limiting (Figure 2A ). Similar results were observed for DNA gap-filling by Polβ, with similar amounts of 32 P-labelled 17-mer converted into 32 P-labelled 18-mer, irrespective of the presence or absence of 5 -AMP ( Figure 2B ). These experiments suggested that neither PNK nor Polβ activity is affected by the presence of 5 -AMP at these time points, and thus short-patch SSBR might fail in AOA1 extracts at the final step of DNA ligation, resulting in the accumulation of adenylated DNA nicks. This was surprising, because adenylated DNA nicks are normal, indeed prerequisite, intermediates of DNA-ligation reactions, requiring only non-adenylated DNA ligase to reseal the breaks. We considered that DNA ligation might fail in AOA1 cell extracts because of insufficient levels of nonadenylated DNA ligase. This would be consistent with the notion that, although DNA ligases exist in both adenylated and non-adenylated states, the former predominates in cells because of the cellular concentration of ATP. This would not be a problem in WT cells, in which aprataxin activity ensures that DNA nicks arising during SSBR are not pre-adenylated and are thus substrates for adenylated DNA ligase. However, in AOA1 cells, DNA nicks arise in a pre-adenylated state during SSBR and thus require non-adenylated DNA ligase. We thus suggest that, whereas all cells possess low levels of non-adenylated ligase, because of the rapid adenylation of free ligase molecules by cellular ATP, only in aprataxindefective cells do pre-adenylated nicks arise at a level sufficient to exceed the availability of non-adenylated ligase.
Evidence in support of this hypothesis arose when we compared WT and AOA1 extracts for their ability to ligate adenylated nicks. Whereas adenylated nicks were efficiently ligated by cell extract from WT cells, they remained largely unligated in reactions containing AOA1 cell extract ( Figure 3A) . To test our hypothesis further, we examined the impact of supplementing short-patch SSBR reactions in AOA1 cell extracts and Aptx −/− mouse neural astrocyte extracts with recombinant DNA ligase. Addition of T4 ligase restored short-patch SSBR efficiency in both AOA1 and Aptx −/− neural cell extract to a level similar to that observed in WT extract ( Figure 3B , compare lanes 6 and 10). Importantly, complementation was more efficient in the absence of ATP than in its presence, supporting the notion that it was the non-adenylated subfraction of T4 ligase that was responsible for complementation ( Figure 3B , compare lanes 8 and 10). The experiments described above suggested that short-patch repair of some adenylated SSBs can occur independently of aprataxin if sufficient non-adenylated DNA ligase is available. To confirm this idea, we also attempted to reconstitute this aprataxin-independent SSBR pathway using recombinant proteins. As expected, the repair of adenylated gaps by PNK, Polβ and Lig3α (DNA ligase IIIα) was dependent on aprataxin in the presence of ATP, conditions under which Lig3α is largely adenylated (Figure 4) . However, in the absence of ATP, short-patch repair of 5 -AMP SSBs occurred independently of aprataxin. Taken together, these experiments indicate that short-patch repair arrests in AOA1 cell extracts at the final step of DNA ligation, owing to insufficient levels of non-adenylated DNA ligase.
The finding that adenylated nicks accumulate during shortpatch SSBR in AOA1 provides a possible explanation for the normal rate of chromosomal SSBR observed in AOA1. This is because adenylated nicks can be channelled into long-patch SSBR. In this pathway, damaged 5 -termini are displaced as a single-stranded flap during gap-filling from the 3 -terminus and cleaved off by FEN1 (flap endonuclease-1) (reviewed in [29] ). This process would not be detected by the shortpatch repair assays employed in our recent work [28] , because oligonucleotide duplexes of the type employed here are not good substrates for long-patch repair reactions and because cleavage of the single-strand flap would remove the 32 P label in our substrates. However, if long-patch repair can compensate for defective short-patch repair in AOA1 cells, then why do aprataxin mutations result in disease? One possibility is that a subset of SSBs arise at which long-patch repair cannot operate. For example, it is possible that aprataxin is also required to repair specific types of damaged 3 -terminus [30] . Long-patch repair would be unable to operate at such breaks, because a 3 -hydroxy primer terminus is not available for DNA gap-filling. Alternatively, since aprataxin is associated with the DSBR machinery [6] , it is possible that unrepaired double-strand breaks might account for AOA1. It should be noted, however, that we have so far failed to detect a DSBR defect in AOA1 or Aptx −/− cells (S. F. EI-Khamisy and K.W. Caldecott, unpublished work). Finally, it is possible that long- patch repair is not operative or is attenuated in the specific cell types that are affected in AOA1. For example, a number of replication-associated proteins, including several of those implicated in long-patch repair, are down-regulated in certain differentiated cell types [31] . 
